Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant i » significant _ (Expand Search), significant co (Expand Search), significant 17 (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant i » significant _ (Expand Search), significant co (Expand Search), significant 17 (Expand Search)
i decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
-
19201
Table 3_The global burden of pediatric infective endocarditis (5–14 years): epidemiological patterns from 1990 to 2021 and projected trajectories.pdf
Published 2025“…DALYs decreased by 19.2% (95% UI, −33.2% to 1.9%). Marked disparities persisted, with high-SDI regions, notably China, achieving the greatest reductions in burden, while sub-Saharan Africa and Eastern Europe exhibited stagnant or increasing rates. …”
-
19202
Data Sheet 3_CD44 knockdown alters miRNA expression and their target genes in colon cancer.pdf
Published 2025“…Introduction<p>Metastasis formation poses a significant challenge to oncologists, as it severely limits the survival of colorectal cancer (CRC) patients. …”
-
19203
Changes in the effective optical zone following hyperopic keratorefractive lenticule extraction
Published 2025“…EOZ reduction was negatively associated with POZ at the late postoperative stage (ΔEOZ/POZ: <i>p</i> = 0.043; ΔEOZ/PTZ: <i>p</i> = 0.020).</p> <p>The EOZ continued decreasing following hyperopic KLEx. …”
-
19204
Supplementary Material for: Efficacy of penetrating canaloplasty versus trabeculectomy in patients with bilateral primary glaucoma: a self-control study
Published 2025“…Complete (without medication) and qualified success (with/without medication) were defined as IOP ≤21 mmHg and ≥20% IOP reduction. Results: Mean IOP decreased from 32.5±8.87mmHg on 2.3±1.43 medications at baseline to 14.6±4.41mmHg on 0.20±0.58 medications at 12 months in TRAB group (both p<0.0001) and from 30.0±9.61mmHg on 2.7±1.10 medications to 14.8±4.63mmHg on 0.12±0.44 medications in PCP group (both p<0.0001). …”
-
19205
Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19206
Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19207
Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19208
Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19209
Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19210
Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19211
Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx
Published 2024“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
-
19212
CO<sub>2 </sub>fertilisation counteracts the negative effect of poor water quality on the growth and photosynthesis of a Great Barrier Reef coralline alga_datasheets
Published 2024“…We found complex interactions between factors on algal growth and photosynthetic rates, but overall, growth was significantly enhanced by <i>p</i>CO<sub>2</sub> enrichment under all light and nutrient combinations. …”
-
19213
Table 9_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19214
Table 2_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19215
Table 10_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19216
Table 3_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19217
Table 8_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19218
Table 6_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19219
Table 5_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”
-
19220
Table 4_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”